Thus, PRMT1, specifically the PRMT1V2 isoform, promotes the pathogenesis of NAFLD by methylating key transcriptional regulators such as PGC‐1α and FOXO1, thereby augmenting hepatic gluconeogenesis and exacerbating hyperglycemia. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.